Helix BioPharma Corp. HBPCF
Set alert
0.77 USD 0.00 0.00%
At close · Oct 30
1.71 Day range 1.71
0.77 52-week range 1.73
- YTD
- -55.49%
- 1 year
- -55.49%
- Open
- 1.71
- Prev close
- 0.77
- Mkt cap
- 58.81M
- Vol
- 100
- Avg vol
- 3
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 1.71
- High
- 1.71
2Y chart
Events in this range
- Dec 16, 2024Earnings: -0.02; estimate 0; surprise —%
Signals (8)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 22, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| RSI: Overbought | Apr 23, 2025 | 1 year ago |
Financials — quick view
HBPCF Revenue — quarterly 1.00M
HBPCF Net income — quarterly -2.87M
HBPCF EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | 0.00 | -0.02 | — | — |
| Oct 24, 2024 | Jul 1, 2024 | 0.00 | -0.08 | — | — |
| Jun 14, 2024 | Apr 1, 2024 | 0.00 | 0.00 | — | — |
| May 13, 2024 | Jan 1, 2024 | 0.00 | 0.00 | — | — |
| Dec 14, 2023 | Oct 1, 2023 | 0.00 | -0.05 | — | — |
| Oct 27, 2023 | Jul 1, 2023 | 0.00 | -0.05 | — | — |
News
- Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
- Helix Biopharma Corp. Announces Board Composition Changes
- Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
- Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
- Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
- Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
- Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
- Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
- Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
- Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Your note
Sign in to keep a note on HBPCF — it syncs with the Stock Master app.